Clinical trial
Efficacy and Safety of Apatinib Mesylate in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma After the Failure of Conventional Treatment: a Phase II Clinical Trial
NCT02976896 is registered in ClinicalTrials.gov with Yuhong Li as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of Apatinib Mesylate in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma After the Failure of Conventional Treatment: a Phase II Clinical Trial
- Lead sponsor
- Yuhong Li
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2016
- Completion date
- December 31, 2022
- Enrollment
- 43 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.